Exabis Library
Welcome to the e-CCO Library!
P627: Stopping anti-tumour necrosis factor (TNF) therapy in patients with perianal Crohn’s disease: Results from a population-based study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P627: Surrogate markers of mucosal healing in Crohn's disease patients in clinical remission under biological/immunomodulator treatment
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P627: Variables associated with evolution to moderate to severe Crohn's disease at two reference centers in Salvador, Bahia, Brazil
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P628 Histological remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P628: Anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis: a systematic review and meta-analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P628: Long-term outcomes with transmural healing vs. mucosal healing in Crohn’s disease: time for new treatment goals ?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P628: Processed and ultra-processed food and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P628: Risk Factors Associated with Extraintestinal Manifestations in Patients with Inflammatory Bowel Diseases
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P628: Tofacitinib in pediatric ulcerative colitis: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHAN
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P628: Transfer of care of adolescent IBD patients without longitudinal transition: Lesson from 10-year experiences
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn’s disease (CD) in real life: Interim analysis of the SUSTAIN study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P629: Efficacy, safety and economic impact of the switch to biosimilar of infliximab in inflammatory bowel disease patients in clinical practice: results of one year
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P629: Evolution of disease phenotype, time to biological therapy and medium-, long-term surgery rates in Crohn’s disease patients in Western Hungary – a population-based study between 2007–2018, data from the Veszprem county cohort
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P629: Impact of surgical treatment on quality of life in Crohn’s disease: Short-and longer-term follow-up
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P629: Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatment
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P629: Rural-urban inequities in Inflammatory Bowel Disease health care access: a population-based retrospective cohort study from a Western Canadian Province
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P629: The initial trough concentration at 36 h after starting tacrolimus is important for the personalised medicine strategy in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P630 Complete endoscopic remission is not only associated with higher mucosal concentrations of 5-aminosalicylic acid but also with N-acetyl-5-aminosalicylic acid in patients with ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P630: A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P630: Development and evaluation of BioCLIA-Tracker infliximab kit: A fast and innovative chemiluminescent assay for the monitoring of patients treated with infliximab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM